Despite advances in medical treatment level, cardiovascular disease remains a major public health issue with high morbidity and mortality worldwide. Cardiac fibrosis characterized by excessive collagen deposition[@b1] is associated with various types of cardiovascular diseases such as heart failure, arrhythmia, and cardiac sudden death. It has been reported that the presence and amount of myocardial fibrosis impacted on arrhythmic outcome and sudden cardiac death in patients with nonischemic dilated cardiomyopathy[@b2]. However, the pathogenesis involved in cardiac fibrosis is not yet well understood. Accumulated evidence indicated that the overstimulation of β-adrenergic receptor (β-AR) induced adverse myocardial remodeling[@b3] and treatment with β~1~-selelctive antagonist was beneficial to cardiac function and structure[@b4]. For instance, previous studies reported that cardiac fibrosis occurred by chronic stimulation with a β~1~/β~2~-adrenoceptor agonist isoprenaline (ISO) or in β~1~-adrenoceptor transgenic mice[@b5]. However, the etiology of cardiac fibrosis induced by β~1~-adrenoceptor has not been revealed completely.

Recently, a large number of clinical investigations have proved that β~1~-adrenoceptor autoantibody (β~1~-AA) was found for high frequency and titers in the sera from patients with dilated cardiomyopathy[@b6], chagas disease[@b7]. heart failure[@b8][@b9] and other diseases[@b10]. Accumulated evidence indicated that β~1~-AA recognized β~1~-adrenoceptor and subsequently activated cyclic adenosine 3′,5′-monophosphate (cAMP)/protein kinase A (PKA), exerting agonist-like effects such as positive inotropic and chronotropic effects[@b11][@b12][@b13]. More interestingly, β~1~-AA-induced increase in beating frequency of neonatal cardiomyocytes remained unchanged for more than 6 h lack of desensitization while ISO underwent desensitization within 60 minutes[@b13]. Badly, long term stimulation with β~1~-AA led to cardiac dysfunction[@b14][@b15], and even increased the susceptibility to arrhythmia[@b16][@b17] as well as sudden cardiac death[@b18][@b19]. In particular, our previous data showed that the positive rate and titer of β~1~-AA were significantly higher in models of heart failure established by abdominal aortic coarctation or doxorubicin injection when myocardial fibrosis simultaneously occurred[@b20]. However, the influence of β~1~-AA on myocardial fibrosis remains little.

Cardiac fibroblast, as the most abundant cell type among the non-cardiomyocytes in the heart, plays numerous roles in cardiac development and remodeling[@b21]. The proliferation and secreting excessive extracellular matrix protein of cardiac fibroblast is concentrated on contributing to cardiac fibrosis[@b22]. Previous evidence showed that p38MAPK[@b23] and ERK1/2[@b24] were involved in proliferation of cardiac fibroblasts. Our previous work suggested that β~1~-AA enhanced proliferation and secretion of lymphocytes through activating β~1~-AR/cAMP/PKA and p38MAPK[@b25]. Others' research reported that β~1~-AA activated ERK1/2 in cardiomyocytes[@b26]. These experimental results, taken together with the expression of β~1~-AR on the surface of cardiac fibroblasts[@b27], suggested that β~1~-AA may be responsible for cardiac fibroblasts proliferation.

This study was designed to establish a passive β~1~-AA immunized mice model to investigate the effect of β~1~-AA on myocardial fibrosis *in vivo* and to determine the impact of β~1~-AA on the proliferation and the underlying mechanisms in cultured cardiac fibroblasts *in vitro*. Our data will provide new experimental evidence for pathological mechanisms of β~1~-AA.

Results
=======

Cardiac fibrosis occurred in a passive immunization mouse model with monoclonal antibodies of β~1~-AR EC~II~
------------------------------------------------------------------------------------------------------------

In order to obtain sufficient β~1~-AA, a monoclonal antibody against the second extracellular loop of β~1~-AR (β~1~-AR mAb) was synthesized by hybridoma technique and purified from the ascites of BALB/c mice using a MabTrap kit. It was clearly displayed that synthesized β~1~-AR mAb had the IgG heavy chains (the relative molecular mass of about 55 KD) and IgG light chains (the relative molecular mass of about 25KD) ([Fig. S1A](#S1){ref-type="supplementary-material"}). Moreover, concentration of β~1~-AR mAb detected by SA-ELISA was much higher compared to β~1~-AA-negative IgG ([Fig. S1B](#S1){ref-type="supplementary-material"}). As shown in [Fig. S1C](#S1){ref-type="supplementary-material"}, primary cultured cardiomyocytes from neonatal rat hearts were isolated successfully and identified by positive α-actinin staining. The spontaneous beating frequency of primary cultured neonatal rat cardiomyocytes was remarkly increased by stimulation of β~1~-AR mAb, which was blocked by β~1~-AR blocker metoprolol and β~1~-AR EC~II~ peptide ([Fig. S1D](#S1){ref-type="supplementary-material"}). Our experimental results indicated that activated β~1~-AR mAb was successfully synthesized, which could be used to the following study.

To create a passive immunization mouse model, synthesized β~1~-AR mAb (hereinafter referred to β~1~-AA) was intraperitoneally injected into the BALB/c mouse at a dose of 5 μg/g body weight once every two weeks during 16 weeks. Our results showed that the level of β~1~-AA remained in the BALB/c mice over time, as indicated by ELISA, suggesting that a passive immunization mouse model with β~1~-AA was established successfully ([Fig. 1A](#f1){ref-type="fig"}). Cardiac function in β~1~-AA and vehicle mice was assessed using M-mode echocardiography. At the 16^th^ week of passive immunization, left ventricular chamber of the mice enlarged in β~1~-AA group ([Fig. 1B](#f1){ref-type="fig"}). The left ventricular ejection fraction (EF) and fractional shortening (FS) began to decrease at the 8^th^ week, and then continued to decrease at the 12^th^ and 16^th^ week ([Fig. 1C,D](#f1){ref-type="fig"}). The results indicated that the systolic cardiac function of β~1~-AA-treated mice was remarkly decreased. Early diastolic and late diastolic mitral flow velocity ratio (E/A Ratio) in β~1~-AA group unchanged during the 16 weeks ([Fig. 1E](#f1){ref-type="fig"}), which suggested that the diastolic cardiac function did not change obviously. All the data suggested that β~1~-AA alone reduced the cardiac function in the mouse model. We also assessed heart structure of the β~1~-AA positive model. As shown in [Fig. 1F--H](#f1){ref-type="fig"}, the ratio of heart weight and body weight began to decrease at the 8^th^ week and decreased more significantly at the 12^th^ and 16^th^ week ([Fig. 1F](#f1){ref-type="fig"}). Left ventricular end-diastolic diameter (LVEDd for short) and left ventricular posterior wall end-diastolic thickness (LVPWT for short) assessed by echocardiography were both enlarged in β~1~-AA group than that in vehicle group at week 12^th^ and 16^th^ ([Fig. 1G,H](#f1){ref-type="fig"}).

Moreover, as early as 8 weeks, the expression of α-SMA in mice heart of β~1~-AA group was much higher than that in vehicle group ([Fig. 2A](#f2){ref-type="fig"}), which highly predicted the phenotypic change of fibroblasts to myofibroblasts contributing to cardiac fibrosis. At the same time, the collagen deposition appeared in the heart of β~1~-AA group ([Supplementary Information Fig. S2](#S1){ref-type="supplementary-material"}). At the 16^th^ week of passive immunization, HE staining showed increased cardiac interstitial and Masson trichrome staining showed greater fibrosic areas with increased collagen deposition in β~1~-AA group than that in vehicle group ([Fig. 2B,C](#f2){ref-type="fig"}), which indicated that β~1~-AA induced cardiac fibrosis. The above-mentioned results indicated that the long term presence of β~1~-AA triggered the cardiac fibrosis.

β~1~-AA promoted proliferation in primary cardiac fibroblasts
-------------------------------------------------------------

To determine the influence of β~1~-AA on proliferation in primary cardiac fibroblasts, we isolated cardiac fibroblasts from neonatal rat heart and detected the effect of β~1~-AA on proliferation of primary cardiac fibroblasts by Cell Counting Kit-8 (CCK-8) and carboxyfluorescein diacetate succinimidyl ester (CFSE) staining. The positivity of cardiac fibroblasts identified by immunofluorescence cellular staining of vimentin was more than 95% ([Fig. S2](#S1){ref-type="supplementary-material"}). The results detected by CCK-8 were as follows: compared to a non-specific IgG group (β~1~-AA negative), 5, 10, and 20 μg/ml of β~1~-AA all markedly increased cell viability of fibroblasts at 24 h while lower concentration 1 μg/ml of β~1~-AA had no proliferation effect ([Fig. 3A](#f3){ref-type="fig"}); positive control β~1~-AR/β~2~-AR isoprenaline (ISO for short, 10^−7^, 10^−6^, and 10^−5 ^mol/L) increased cell viability of cardiac fibroblasts in a concentration-dependent manner at 24 h ([Fig. 3B](#f3){ref-type="fig"}). The results showed that 10 μg/ml β~1~-AA or 10^−6 ^mol/L ISO obviously promoted proliferation of cardiac fibroblasts. Thus, 10 μg/ml β~1~-AA or 10^−6 ^mol/L ISO were used to explore the specific proliferation mechanisms in the following study. Indeed, analysis of CFSE staining by flow cytometry clearly showed that the proliferation index of cardiac fibroblasts treated with either 10 μg/ml β~1~-AA or 10^−6 ^mol/L ISO for 24 h was elevated in cardiac fibroblasts than that of cardiac fibroblasts treated with the non-specific IgG or vehicle respectively ([Fig. 3C](#f3){ref-type="fig"}). Additionally, cell morphology was observed by immunofluorescence cellular staining of vimentin using a laser scanning confocal microscope. As shown in [Fig. 3D](#f3){ref-type="fig"}, cardiac fibroblast which had two or three nucleus increased after stimulation with either β~1~-AA or ISO for 24 h, suggesting that β~1~-AA enhanced proliferation of cardiac fibroblasts.

β~1~-AA bound to β~1~-AR in cardiac fibroblast directly
-------------------------------------------------------

To explore the underlying mechanisms of β~1~-AA on proliferation of cardiac fibroblasts, we analyzed the direct binding of β~1~-AA and β~1~-AR in cardiac fibroblasts by immunofluorescence cellular staining, immunoprecipitation and BLItz system. Results showed that β~1~-AA used as the primary anti-β~1~-AR in the present study bound to β~1~-AR on the surface of cardiac fibroblasts directly, while non-specific IgG did not ([Fig. 4A](#f4){ref-type="fig"}). Immunoprecipitation results displayed that β~1~-AA as well as a purchased β~1~-AR primary antibody interacted with β~1~-AR in cardiac fibroblast, while non-specific IgG did not bind to β~1~-AR ([Fig. 4B](#f4){ref-type="fig"}). In addition, BLItz system further confirmed the direct binding of β~1~-AA and β~1~-AR. The kd value of purchased anti-β~1~-AR and β~1~-AA binding to cardiac fibroblasts were 3.411e^−3 ^mol/L and 3.455e^−3 ^mol/L respectively while the kd value of non-specific IgG binding to cardiac fibroblasts was less than 1e^−7 ^mol/L. The data showed that the affinity of β~1~-AA (or a purchased anti-β~1~-AR antibody) and cardiac fibroblast were both much higher than non-specific IgG, which significantly suggested the specific binding of β~1~-AA and β~1~-AR in cardiac fibroblasts ([Fig. 4C](#f4){ref-type="fig"}).

β~1~-AA promoted proliferation in cardiac fibroblast partially through β~1~-AR/cAMP/PKA
---------------------------------------------------------------------------------------

β~1~-AR/cAMP/PKA is the classical signaling of exerting physical and pathological effects in cardiac cells. PKA-substrate vasodilator-stimulated phosphoprotein (VASP) is a key effector of cAMP, whose principal function is regulated by PKA via phosphorylation at Ser^157^ [@b28]. To determine whether the β~1~-AR/cAMP/PKA pathway was involved in proliferation of cardiac fibroblast induced by β~1~-AA, cardiac fibroblasts were pretreated with the β~1~-selective antagonist blocker metoprolol or the PKA inhibitor H89 for 30 min before treatment with β~1~-AA. Results showed that metoprolol partially blocked the proliferation effects of β~1~-AA on cardiac fibroblasts and that the supernatant from incubation of β~1~-AA and β~1~-AR EC~II~ reversed the effects completely ([Fig. 5A](#f5){ref-type="fig"}), which suggested β~1~-AA promoted proliferation of cardiac fibroblasts partially through β~1~-AR. Similarly, CFSE staining assay showed that the cell viability of cardiac fibroblasts stimulated by β~1~-AA was partially reversed by pretreatment with metoprolol or β~1~-AR EC~II~ ([Fig. 5B](#f5){ref-type="fig"}). In addition, β~1~-AA increased the concentration of intracellular cAMP of cardiac fibroblasts, which was blocked by metoprolol partially ([Fig. 5C](#f5){ref-type="fig"}). Pretreatment with PKA (downstream of cAMP) inhibitor H89 for 30 min before adding β~1~-AA also partially reversed the increased cell viability induced by β~1~-AA ([Fig. 5D](#f5){ref-type="fig"}). PKA activity monitored by ratio of p-VASP/VASP protein in cardiac fibroblasts increased by stimulation with β~1~-AA, which was reversed partially by pretreatment of metoprolol or H89 ([Fig. 5E](#f5){ref-type="fig"}). Interestingly, β~1~-AA persistently activated PKA activity in 1 h which is different from agonist-induced desensitization ([Fig. 5F](#f5){ref-type="fig"}). All of these results indicated that β~1~-AA stimulated cardiac fibroblasts proliferation at least partially through the β~1~-AR/cAMP/PKA pathway.

Involvement of β~2~-AR in β~1~-AA-mediated proliferation in cardiac fibroblast
------------------------------------------------------------------------------

β~2~-AR plays a significant role in proliferation of cardiac fibroblasts. To examine whether β~2~-AR was involved in fibroblasts proliferation induced by β~1~-AA, specific β~2~-AR blocker ICI118551 were pretreated before stimulation of β~1~-AA in cardiac fibroblasts. Results showed that ICI118551 also partially reversed the proliferation effect induced by β~1~-AA ([Fig. 6A](#f6){ref-type="fig"}). And similar to β~1~-AR blocker metoprolol, ICI118551 reduced the increased cAMP induced by β~1~-AA in part ([Fig. 6B](#f6){ref-type="fig"}). However, β~2~-AR expression of cardiac fibroblasts was unchanged after stimulation with β~1~-AA for 24 h ([Fig. 6C](#f6){ref-type="fig"}). Above-mentioned results suggested that β~2~-AR might be involved in proliferation of fibroblasts induced by β~1~-AA.

To explore why β~2~-AR were involved in β~1~-AA mediated fibroblasts proliferation, we examined the binding of β~1~-AA and β~2~-AR by gene transfection, immunoprecipitation and BLItz system. HA-β~1~-AR or flag-β~2~-AR was overexpressed on HEK293 cells by plasmid transfection respectively. In immunoprecipitation experiments, β~1~-AA interacted with β~1~-AR in HEK293 cells which were β~1~-AR-overexpressed ([Fig. 6D.a](#f6){ref-type="fig"}), but not with β~2~-AR in HEK293 cells which were β~2~-AR-overexpressed ([Fig. 6D.b](#f6){ref-type="fig"}). In agreement with above results, BLItz system results displayed that β~1~-AA directly bound to cell lysis of β~1~-AR-overexpessed HEK 293 cells, but not to cell lysis of β~2~-AR-overexpessed HEK 293 cells, which clearly suggested that β~1~-AA bound to β~1~-AR directly but not to β~2~-AR. ([Fig. 6D.c,D.d](#f6){ref-type="fig"}).

Involvement of p38MAPK and ERK1/2 in β~1~-AA-mediated proliferation in cardiac fibroblasts
------------------------------------------------------------------------------------------

P38MAPK plays a key role in regulating the proliferation of cardiac fibroblasts. In immunoblot analysis, β~1~-AA resulted in increased p38MAPK phosphorylation in cardiac fibroblasts at 30 min, while total p38MAPK remained unchanged ([Fig. 7A](#f7){ref-type="fig"}). Moreover, phosphorylated p38MAPK began to increase after stimulation of β~1~-AA for 15 min and still increased at 1 h ([Fig. 7B](#f7){ref-type="fig"}). To determine the involvement of p38MAPK in cardiac fibroblasts proliferation, the selective p38MAPK inhibitor SB203580 (1 μmol/L) was used to block the pathway before applied with β~1~-AA (10 μg/ml). As depicted in [Fig. 7C](#f7){ref-type="fig"}, the proliferation of cardiac fibroblasts stimulated by β~1~-AA was partially inhibited by SB203580. These data demonstrated that a role of p38MAPK activation in cardiac fibroblast proliferation was mediated by β~1~-AA. Similarly, β~1~-AA increased phosphorylated ERK1/2 ([Fig. 7D](#f7){ref-type="fig"}), and β~1~-AA was likely to promote the proliferation at 24 h through ERK1/2 as ERK1/2 PD98059 partially reversed the proliferation ([Fig. 7E](#f7){ref-type="fig"}). Taken together, both the activation of p38MAPK and ERK1/2 were involved in the production of cardiac fibroblasts stimulated with β~1~-AA.

Conditioned medium of cardiac fibroblasts stimulated by β~1~-AA promoted cardiomyocyte early apoptosis
------------------------------------------------------------------------------------------------------

To determine whether β~1~-AA promoted the secretion of cardiac fibroblasts, the supernatant of neonatal rat cardiac fibroblasts was harvested after stimulation of β~1~-AA for 24 h and added to cardiomyocytes to detect the cell viability and apoptosis of neonatal rat cardiomyocytes for 24 h. Here β~1~-AA included in the supernatant was neutralized by co-incubation with β~1~-AR-EC ~II~ for 1h at 37 °C, in order to rule out the influence of β~1~-AA on cardiomyocyte. As a result, the conditioned medium of β~1~-AA activated cardiac fibroblasts indeed increased early apoptosis of cardiomyocyte and H9c2 cell lines at 24 h detected by an Annexin V/PI apoptosis kit ([Fig. 8A](#f8){ref-type="fig"},B), which indicated that the conditioned medium of cardiac fibroblasts induced by β~1~-AA promoted early apoptosis of cardiomyocytes, which indicated that β~1~-AA changed the secretion of cardiac fibroblasts.

Discussion
==========

In the present study we demonstrate that the presence of β~1~-AA directly trigger cardiac dysfunction and collagen deposition in a β~1~-AR monoclonal antibody-positive mouse model. Further, we provide the first evidence that β~1~-AA can promote proliferation in cardiac fibroblasts partially through β~1~-AR, β~2~-AR, P38MAPK and ERK1/2 pathway *in vitro*. Interestingly, β~1~-AA activated the downstream signalling PKA and P38MAPK in 1 h.

A lot of clinical investigations reported that the prevalence of β~1~-AA induced cardiac dysfunction in patients with a variety of cardiovascular diseases[@b9]. The removal of circulating autoantibodies had beneficial effects on cardiac function of some patients with cardiomyopathy and heart failure[@b29]. To explore the underlying pathological mechanism of β~1~-AA, a β~1~-AA positive model in mouse seems to be essential. As illustrated in previous studies, β~1~-AA was obtained from sera of β~1~-AA-positive patients[@b25] or active β~1~-AR EC~II~ immunized animals[@b14]. However, it seems that so-called β~1~-AA did not reflect the biological effects of β~1~-AA completely because of the non-specific IgG involved in. Here we obtained a monoclonal antibody against β~1~-AR-EC~II~ using hybridoma technology in order to eliminate the interference of non-specific IgGs. This "synthetic" β~1~-AA bound to β~1~-AR by SA-ELISA and increased the beating rate of neonatal rat cardiomyocytes by activating β~1~-AR, indicating that anti-β~1~-AR monoclonal antibody exhibited functional activity. As a result, we used anti-β~1~-AR monoclonal antibody as β~1~-AA in our studies.

Previously, a β~1~-AA-positive model was created using synthetic peptide corresponding to β~1~-AR-EC~II~[@b30]. However, such antigens can't be excluded themselves as pathological causes of myocardial injury on the body. In present study, anti-β~1~-AR monoclonal antibodies were intraperitoneally injected into BALB/c mice to establish a passive β~1~-AA immunized mice model, in which the concentration of β~1~-AA matched that of clinical cardiovascular patients very closely by using SA-ELISA[@b25]. Cardiac function, in terms of ejection fraction and fractional shortening[@b31] in this model was assessed by M-mode ultrasound. Our results showed that β~1~-AA exposure in mice for 16 weeks worsen the systolic function in terms of decreased EF and FS while the diastolic function did not change because of unchanged E/A ratio. Furthermore, it showed the left ventricular dilated change and declined HW/BW in β~1~-AA treated mice, which may indicate that there is a massive of cardiomyocytes death due to cardiomyocytes apoptosis[@b32] or autophagy[@b14]. Additionally, the heart rate did not change during passive β~1~-AA immunization for 16 weeks in the current study ([Supplementary material 3](#S1){ref-type="supplementary-material"}). Maybe it should be observed for a longer time, it will be in agreement with the decreased heart rate previously[@b30]. And we further confirm that β~1~-AA is an independent risk factor of cardiac dysfunction which are consistent with previous reports[@b33][@b34]. Furthermore, we showed that the expression of α-SMA by immunofluorescence labeling increased in β~1~-AA group as early as the 8^th^ week, which suggested that the phenotypic change of fibroblasts to myofibroblasts. And at the same time, collagen deposition occurred in the mice heart of β~1~-AA group ([Supplementary material 2](#S1){ref-type="supplementary-material"}). At the 16^th^ week, we found that the area of collagen deposition in the passive β~1~-AA immunized mouse model by Masson staining was much larger than that in the saline group. These results indicated that the existence of β~1~-AA induced cardiac fibrosis. We believe that β~1~-AA contribute to myocardial fibrosis in patients with heart failure. However, it should be noted that this study has examined only a phenomenon of β~1~-AA mediated cardiac fibrosis.

Proliferation of cardiac fibroblasts is a determinant factor in maintaining cardiac extracellular matrix and fibrotic myocardial remodeling in injured and failing hearts[@b21]. We found the novel results that cell viability and proliferation index of cardiac fibroblasts were both enhanced by stimulation with β~1~-AA. Then, the problem is how β~1~-AA alone promotes proliferation in cardiac fibroblasts. It has been reported that β~1~-AR/cAMP/PKA signaling is the typical manner of β~1~-AA activating cell. We have previously shown that β~1~-AA promoted proliferation of T lymphocytes via β~1~-adrenocptor/cAMP/PKA pathway. It has been reported that β~1~-AR was expressed in cardiac fibroblasts[@b27]. In addition, it has been reported that β~1~-AA induced the overexpression of fibroblast CD40 and trigger generation of protaglandin E2[@b35][@b36]. Here we put forward thatβ~1~-AA activated β~1~-AR in cardiac fibroblasts. Moreover, we showed that β~1~-AA mediated proliferation of cardiac fibroblasts partially via β~1~-AR/cAMP/PKA pathway, which is similar to T lymphocytes proliferation induced by β~1~-AA[@b25] while isopposite to β~1~-AA mediated apoptosis of cardiomyocytes[@b32].

The remaining problem is what is the other pathway involved in β~1~-AA-induced cardiac fibroblast proliferation. Recent studies implied that β~2~-AR mediated the proliferation of cardiac fibroblasts induced by β~1~/β~2~-adrenoceptor agonist ISO[@b23]. There are a lot of similarity between β~1~-AR and β~2~-AR on the structure, and they not only have the same Gs pathway but also both cause Gs/Gi switching[@b37]. For this reason, we assume that the interaction between β~1~-AR and β~2~-AR might be involved in the proliferation of cardiac fibroblasts induced by β~1~-AA. In present study, pretreatment with β~2~-AR selected antagonist ICI118551 partially reversed proliferative effect induced by β~1~-AA. However, β~1~-AA did not change the expression of β~2~-AR in cardiac fibroblasts at 24 h. To our knowledge we this study provides the first evidence indicating that β~2~-AR may participate in the fibroblasts proliferation induced by β~1~-AA. However, these findings were not used to determine how β~1~-AA induced the interaction of β~1~-AR and β~2~-AR.

A large number of publications already described the involvement of MAPK in the induction of proliferation after treatment of various cell types with different mitogens[@b38]. We previously demonstrated that β~1~-AA was likely to promote proliferation in T lymphocytes through p38MAPK[@b25]. Here we found that β~1~-AA increased the level of phosphorylated p38MAPK and ERK1/2 in cardiac fibroblast, which is similar to previous study. We have demonstrated that p38MAPK may be involved in the proliferation of cardiac fibroblasts. Besides, β~1~-AA activated ERK1/2[@b29] and p38MAPK[@b24]. Interestingly, β~1~-AA persistently activated p38MAPK in 1 h which indicated that β~1~-AA activated cardiac fibroblast lack of desensitization. This effect is different from that isoprenaline. Recent study reported that the downstream of cAMP Epac mediated MAPK played a significant role in proliferation of cardiac fibroblasts[@b39], however, whether activated MAPK induced by β~1~-AA was mediated by Epac, which will be explore in the further study.

Recently, it is reported that β~1~-AA activated β~1~-AR in the neonatal rat cardiomyocytes which lacked desensitization of β~1~-AR[@b13]. In this study, we determined the downstream signalling of β~1~-AR in cardiac fibroblasts treated with β~1~-AA. We found that β~1~-AA activated PKA and P38MAPK in 1 h. And the endocytosis of β~1~-AR expressed on the surface of HEK 293 cells was lower than in that induced by agonist isoprenaline (data not shown), which is consistent with reported research[@b40]. Our findings further supported the result β~1~-AA did not induce agonist-induced desensitization[@b13], which deserve attention in the future study.

Evidence has shown that, under physiological conditions, cardiac fibroblasts secreted brain natriuretic peptide, extracellular matrix, IL-6, TGF-β, and other compounds that help regulate cardiac function[@b41]. However, the excessive extracellular matrix deposition contributes to cardiac dysfunction. A previous research suggested β~1~-AA induced fibroblast CD40 and triggered prostaglandin E2 generation[@b35]. Our results indicated that conditioned medium of cardiac fibroblasts treated with β~1~-AA changed the secretion of cardiac fibroblasts, which promote apoptosis of cardiomyocytes. Here, the conditioned medium including β~1~-AA was neutralized by β~1~-AR EC~II~ to rule out the effects of β~1~-AA on the cardiomyocytes. Results showed that the conditional medium of cardiac fibroblasts promoted apoptosis in cultured neonatal rat cardiomyocytes and H9c2 cardiac cell lines, and the apoptotic baseline of rat neonatal cardiomyocytes was much greater than that of H9c2 cardiac cells. we observed that rat neonatal cardiomyocytes indicated by an Annexin V/PI kit may be more susceptible to early apoptosis than H9c2 cardiac cells, indicating that H9c2 cardiac cells are appropriate for studies of apoptosis. These results suggest that β~1~-AA results in injury to cardiac cells indirectly in a manner of activating fibroblasts. Yet we do not clarify underlying factors that may be involved in the changed secretion of cardiac fibroblasts induced by β~1~-AA, which are critical requirements.

In summary, β~1~-AA-positive passive mice model is generated to study the pathological mechanism of β~1~-AA-mediated cardiovascular diseases. In the model, we show that the long term presence of β~1~-AA alone may contribute to cardiac fibrosis and cardiac dysfunction. *In vitro*, β~1~-AA promoted the proliferation and secretion of cardiac fibroblasts through β~1~-AR/β~2~-Adrenoceptor. Our study will help understand the pathological mechanism of β~1~-AA.

However, β~1~-AA induced the proliferation and secretion of cardiac fibroblasts is just one of the causes in cardiac fibrosis, and our limitation is that we did not supply for pre-treatment of β~1~-AR blocker metoprolol and PKA inhibitor H89 in mice model. Additionally, recent study showed that endothelial dysfunction preceded LV dysfunction related to fibrosis. It has been reported that β~1~-AA induced endothelial dysfunction in conductance and resistance arteries of the wistar rat[@b42], which indicated that autoantibody might exert deleterious effect on coronary vasomotricity. However, a lot of experiments need to do in order to clarify the hypothesis and the corresponding mechanisms. And we will study on it in the further study.

In addition, a lot of factors are involved in cardiac fibrosis, such as apoptosis of cardiomyocytes, excessive pressure loading. It has been reported that knockout of β~1~-AR attenuated pressure overload-induced cardiac fibrosis[@b43], which suggested that β~1~-AR was involved in the pressure overload-induced fibrosis. Here tail pressure in mice of β~1~-AA group exhibited higher systolic blood pressure as well as unchanged diastolic blood pressure compared with vehicle group ([Supplementary material 4](#S1){ref-type="supplementary-material"}). However, whether the increased systolic blood pressure was involved in β~1~-AA induced cardiac fibrosis and the underlying mechanisms needs to be clarified by a lot of experiments in the further study. Additionally, many evidence demonstrated that galectin-3 is closely related to cardiac fibrosis even may be a predictor of heart failure[@b44][@b45]. However, whether galectin-3 is involved in β~1~-AA mediated cardiac fibrosis is unknown, which may be the new direction of our study.

Materials and Methods
=====================

Preparation of monoclonal antibodies to β~1~-adrenoceptor
---------------------------------------------------------

Long peptide (H-W-W-R-A-E-S-D-E-A-R-R-C-Y-N-D-P-K-C-C-D-F-V-T-N-R-C) and short peptide (C-H-W-W-R-A-E-S-D-E-A-R-R) were respectively synthesized according to the amino acid sequence of the second extracellular loop of β~1~-adrenergic receptor (β~1~-AR-EC~II~, 197aa-223aa, H-W-W-R-A-E-S-D-E-A-R-R-C-Y-N-D-P-K-C-C-D-F-V-T-N-R-A, the homology rate among human, mouse and rat is 100%) and were coupled as an antigen for immunizing mice. Hybridoma cell lines secreting β~1~-AR monoclonal antibody (β~1~-AR mAb) were generated by hybridoma technology. β~1~-AR mAb were purified from the ascites of BALB/c mice using a MabTrap kit (Amersham Biosciences). The concentration of β~1~-AR mAb and specificities were determined using a BCA Protein Assay kit (Pierce, Rockford, USA) The binding of β~1~-AR mAb and β~1~-AR was detected by ELISA. And the functional activity of β~1~-AR mAb was tested by neonatal mouse cardiomyocytes beating frequency.

Generation of β~1~-AA passive immunization model in mice
--------------------------------------------------------

BALB/c mice used in the experiment were healthy, male, 8-week-old from the Experimental Animal Center of Capital Medical University. Animal experiments were performed in compliance with The Guide for the Care and Use of Laboratory Animals published by the National Institutes of Health (NIH Publication No. 85-23, Revised 1996). The study was approved by the Institutional Animal Care and Use Committee of Capital Medical University and the Guide for the regulation in the People's Republic of China.

The mice which were sera-negative for β~1~-AA were selected and randomly divided into β~1~-AA positive group and vehicle group. β~1~-AA positive mice model was established by intraperitoneal injection of monoclonal antibodies against β~1~-AR EC~II~ in a dose of 5 μg/g body weight once every two weeks during 16 weeks while the vehicle group was treated in the same way with saline. The sera were obtained in both of the two groups before each treatment. β~1~-AA was measured in sera using Enzyme-linked immunosorbent assay (ELISA) as previously described[@b30] and results were expressed as absorbance (*A*) value.

Echocardiography
----------------

For echocardiography, mice were anesthetized with 1.5% isoflurane. Two-dimensional (2D) echocardiographic views of the mid-ventricular short axis were obtained at the level of the papillary muscle tips below the mitral valve (Vevo 770, VisualSonic, Canada). Left ventricular ejection fraction (EF), fractional shortening (FS) and early diastolic and late diastolic mitral flow velocity ratio (E/A Ratio) were calculated by the parameters as the assessment of cardiac function in mice[@b31]. Left ventricular end-diastolic diameter (LVEDD), left ventricular posterior wall end-diastolic thickness (LVPWT) and left ventricular mass (LV mass) measured by M-mode echocardiography evaluated the structure of left ventricular.

Masson trichrome
----------------

At the end of immunization at 16 weeks, mice of β~1~-AA and vehicle group were killed. Heart tissues were taken from mice quickly and fixed by 4% paraformaldehyde in phosphate buffered saline (PBS) for 48 hours, embedded in paraffin and sectioned (4 μm). Samples were then stained with Masson Trichrome staining for evaluation of collagen deposition. All tissue slides were analyzed by optical microscopy (Olympus BX45, Olympus Corporation, Tokyo, Japan) by the double-blind fashion.

Immunofluorescence
------------------

At the 8^th^ week of immunization, mice of β~1~-AA and vehicle group were killed. Heart tissues were taken from mice quickly and fixed by 4% paraformaldehyde in PBS for 48 hours, embedded in paraffin and sectioned (4 μm). Samples were then stained with immunofluorescence labeling of α-SMA for evaluation of fibrogenic myofibroblasts. Anti-α-SMA primary antibody (1:100 dilution, Abcam, Cat. No. ab5694) was added to the section of heart tissue overnight at 4 °C in the experiment. After three washes with PBS, samples were probed with a fluorescently labeled TRITIC (1:200 dilution, ZSGB-BIO, Cat. No. ZF-0313) secondary antibody for 1 h at room temperature. Following washout, cells were dyed using DAPI and imaged on the fluorescence microscope.

Cell culture
------------

Cardiac fibroblasts and cardiomyocytes were isolated from neonatal rat (1--3 days old) using trypsin and collagenase II. H9c2 myocardial cell line and HEK 293 cells were from China Infrastruture of Cell Line Resources. Cells were placed into culture media (DMEM, 10% normal bovine serum and 100 U/ml penicillin/streptomycin) and were incubated in incubator with 5% CO~2~ and 95% air at 37 °C. The neonatal rat cardiac fibroblasts and cardiomyocytes were examined for positivity for vimentin and α-actinin respectively. Fibroblasts in passages 3--6 were placed in serum-free-medium for 24 h before each treatment. There were no contaminated cells used in the present study.

Cardiac fibroblasts proliferation
---------------------------------

### Cell viability assay

Cell viability was measured with a cell counting kit-8 (CCK-8). Cardiac fibroblasts were cultured in either the presence or absence of PBS, β~1~-AA-negative mouse IgG (1 μg/ml, 5 μg/ml, 10 μg/ml, 20 μg/ml), β~1~-AA (1 μg/ml, 5 μg/ml, 10 μg/ml, 20 μg/ml), Isoprenaline (10^−8^mol/L, 10^−7^mol/L 10^−6^mol/L, 10^−5^mol/L), β~1~-AR blocker metoprolol, PKA inhibitor H89 and β~2~-AR blocker ICI118551 in 96-well plate for 24 h. Blockers were added 1 h before β~1~-AA. After each treatment, 10  μl CCK-8 (Dojindo Molecular Technologies, CK04, Kumamoto, Japan) solution was added to each well and the cells were incubated at 37 °C for 2 h in 5% CO~2~ incubator. The absorbance of each well was measured at a wavelength of 450 nm with a microplate reader by the following equation: viability %= \[(AS-AB)/(AC-AB)\] × 100%, where AS is the absorbance of the samples, AC is the absorbance of the DMEM media, and AB is the absorbance of the control.

### CFSE labeling and analysis

CFSE is used for cell tracking and proliferation studies. Cardiac fibroblasts were labeled with 5 μmol/L CFSE (Invitrogen Corporation) for 15 min. After the treatments were performed for 24 h, cardiac fibroblasts were harvested and analyzed by flow cytometry. The proliferation index of cardiac fibroblasts was analyzed by Modfit analysis software.

Binding of β~1~-AA and β~1~-AR
------------------------------

### Immunofluorescence cellular staining

Cultured cardiac fibroblasts in 24-well-plate which was pretreated with poly-L-lysine were fixed for 30 min at room temprature in 4% paraformaldehyde, followed by three washes with phosphate buffered saline (PBS). Cells were permeabilized with 0.1% TritonX-100 in PBS for 10 minutes and blocked with 5% normal goat serum for 1 h. We used the following primary antibodies in our studies: vimentin (1:200 dilution, Sigma-Aldrich, Cat. No. V6389), α-actinin (1:1000 dilution, Sigma-Aldrich, Cat. No. A7811) and β~1~-adrenergic receptor (1:200 dilution, Abcam, Cat. No. ab3442). After three washes with PBS, samples were probed with a fluorescently labeled TRITIC (1:200 dilution, ZSGB-BIO, Cat. No. ZF-0313) or FITC (1:200 dilution, ZSGB-BIO, Cat. No. ZF-0311) secondary antibody or for 1 h at room temperature. Following washout, cells were dyed using DAPI and imaged on the laser scanning confocal microscope for the cellular identification and expression of β~1~-AR.

### Protein-protein interaction

The interaction between β~1~-AA and β~1~-AR (or β~2~-AR) was analyzed using the BLItz system (ForteBio, Menlo Park, CA). Non-specific mouse IgG (Sigma-Aldrich. Cat. No. ab3442), purchased primary anti-β~1~-AR (Abcam, Cat. No. ab3442), purchased primary anti-β~2~-AR (Abcam, Cat. No. ab182136) or β~1~-AA attached to protein A/G biosensors respectively (Fortebio). Next, cardiac fibroblasts or HEK 293 cells which were lysed using cell lyse buffer were added to detect the direct binding of cells and above antibodies pre-bound to the protein A/G biosensor. The steps in cardiac fibroblsts were as follows: initial baseline for 120 s, loading for 240 s, baseline for 120 s, association for 240 s, and dissociation for 240 s. The affinity value of the binding of β~1~-AA and β~1~-AR was generated by BLItz pro software analysis.

### Immunoprecipitation

Cells were lysed in immunoprecipitation buffer. 500 μg of cell lysate was incubated with or without 500 ng/ml Protein A/G (Santa Cruz Biotechnology) at 4 °C for 4 h. Immune complexes were precipitated with the magnetic beads that were pre-bound with appropriate antibodies (IgG, rabbit polyclonal anti-β~1~-AR primary antibodies, rabbit polyclonal anti-β~2~-AR primary antibodies or β~1~-AA) overnight at 4 °C, followed by four washes with the immunoprecipitation buffer. Immune complexes were then eluted from the beads with 2 × SDS sample buffer and subjected to SDS-PAGE.

### Determination of cAMP production

Cardiac fibroblasts were seeded in 24-well plates at a density of 1 × 10^5^ cells/well. cAMP production of cells was measured after different treatment for 15 min at 37 °C in a humidified incubator in HEPES containing 1 mM 3-isobutyll-methylxanthine (IBMX; Sigma, St. Louis, MO, USA). The cAMP content of the cell lysate was determined by \[^125^I\] cAMP Radio-Immunoassay KIT according to the manufacturer's protocol. The assay is based on the competition between unlabelled cAMP and fixed quantity of \[^125^I\] labelled cAMP-specific antibody, and the cell-associated radioactivity was counted in a 1470 Wallac Wizard γ counter (Perkin Elmer).

### Western blot analysis

To perform PKA activity, phospho-vasp^Ser\ 157^ and total-vasp were analyzed by western blot[@b25], after a rapid rinse with PBS, cardiac fibroblasts were scraped from 6-well multi-well plates, lysed with RIPA buffer supplemented with protease inhibitor and phosphatase inhibitor. Total protein concentration in each sample was measured by the BCA assay using bovine serum albumin as the standard protein. A fixed amount of protein (30 μg) from each sample was fractionated in 12% SDS-polyacrylamide gels by electroresis and then transferred to immobilon-FL PVDF membranes (Millipore, IPVH00010). Blots were probed using rabbit anti-phospho-vasp ^Ser\ 157^ (1: 1000, Cell Signaling Technology, Cat. No. 3111) or anti-total-vasp antibodies (1:1000, Cell Signaling Technology, Cat. No. 3112). Mouse anti-GAPDH (1:1000, Sigma-aldrich, Cat. No. SAB1405848) or β-actin (1:1000, Cell Signaling Technology, Cat. No. 12620) was used as protein loading control. All bands were normalized to their respective controls.

### Transfection

HEK293 cells plated in a 6-well plate were transfected with HA-β~1~-AR or flag-β~2~-AR plasmid DNA using Lipofectamine 2000 transfection reagent (Invitrogen, Cat. No. 11668019) following the manufacturer's recommendations. Experiments were performed 24 h after the transfection.

### Assessment of cell apoptosis

Conditioned medium of different treatment of cardiac fibroblast for 24 h was added to NRCMs and H9c2 myocardial cells for 24 h. NRCMs and H9c2 were harvested, washed and re-suspended in binding buffer 24 h after stimulation. The apoptosis of cells was determined with an FITC Annexin V/PI apoptosis detection kit according to the instructions of the manufacturer. Briefly, cells were washed three times in PBS and subsequently in the dark in 200 μl of binding buffer containing 10 μl Annexin V- FITC and 5 μl of propidium iodide (PI). Afterward, cell apoptosis was analyzed by flow cytometry within 1 h.

### Statistics

All statistical analysis was performed using of SPSS 15.0 statistical software. One way-ANOVA followed by post hoc Bonferroni correction was performed on proliferation of fibroblasts among different groups. All the experimental data were expressed as mean ± standard error. Repeated measurement data analysis of variance was using for continuous measurement of the experimental data at different time points, probabilities of 0.05 or less was considered statistically significant.
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![Cardiac function in vehicle and β~1~-AA positive mice model during treated 16 weeks.\
(**A**) The level of β~1~-AA at different time points during the treated 16 weeks. (**B**) Images are representative of echocardiogram at the 16^th^ week. (**C--H**) The LVEF % (left ventricular ejection fraction), FS% (fraction shortening), E/A ratio, heart weight/Body weight (HW/BW), left ventricular end diastolic dimension (LVEDd, mm) and left ventricular posterior wall end-diastolic thickness (LVPWT, mm) of β~1~-AA positive group and vehicle group mice during the 16 weeks. Data are presented as mean ± SEM. ^\*^*P* \< 0.05 *vs.* vehicle group, ^\*\*^*P* \< 0.01 *vs.* vehicle group, n = 8/group at different time points.](srep32430-f1){#f1}

![Cardiac fibrosis occurred in β~1~-AA positive mice.\
(**A**) The expression of α-smooth muscle actin (α-SMA) in the heart of vehicle and β~1~-AA group at the 8^th^ week of model. (**B**) The morphology of heart in vehicle and β~1~-AA group determined by HE staining at the 16^th^ week of model. (**C**) Collagen deposition of heart in vehicle and β~1~-AA positive group detected by Masson Trichrome staining at the 16^th^ week of model. Scale bar = 500 or 50 μm, respectively.](srep32430-f2){#f2}

![β~1~-AA increased cell viability of cardiac fibroblasts (CFs).\
(**A,B**) Different concentrations of β~1~-AA and β~1~/β~2~-AR agonist isoprenaline (ISO) were added to cultured cardiac fibroblasts respectively for 24 h, then the cell viability was detected by Cell Counting Kit-8. n = 6 per group. (**C**) CFs before different treatments were labeled with 5 μmol/ml CFSE and cell proliferation was measured by flow cytometry. Data shown here are representative of one of three individual experiments with similar results. The bar graph showed the statistical results. (**D**) The morphology of cardiac fibroblasts treated with β~1~-AA and ISO. Vimentin, which is a marker of cardiac fibroblasts, was detected using immunofluorescence and observed in confocal microscopy. After β~1~-AA and ISO were added to cardiac fibroblasts and allowed to incubate for 24 h, the morphology of cardiac fibroblasts changed. The cells had more cytoplasm and there were more two-nucleus cells. All data are presented as the mean ± SEM of three independent experiments. ^\*\*^*P* \< 0.01 *vs.* vehicle group, ^\#\#^*P* \< 0.01 *vs.* IgG group. (β~1~-AA negative IgG). IgG: β~1~-AA-negative mouse IgG.](srep32430-f3){#f3}

![β~1~-AA bound to β~1~-AR in cardiac fibroblasts.\
(**A**) The binding of β~1~-AA/purchased anti-β~1~-AR primary antibody to β~1~-AR by immunfluorescence cellular staining. (**B**) The BLItz system results for the interaction of β~1~-AA-negative mouse IgG (yellow line), β~1~-AA (red line) and purchased anti-β~1~-AR primary antibody (green line) with β~1~-AR in CFs are shown. The vertical and horizontal axes represent the light shift distance (nm) and association/dissociation time (sec), respectively.](srep32430-f4){#f4}

![β~1~-AA induced the proliferation of cardiac fibroblasts (CF) partially via the β~1~-AR/cAMP/PKA pathway.\
(**A**) CF was pretreated with the selective β~1~-AR antagonist metoprolol (1 μmol/ml) for 30 min before adding β~1~-AA (10 μg/ml). Cell viability of CF was detected by CCK8 assay. (**B**) Increased proliferation index induced by β~1~-AA was partially reversed by β~1~-AR antagonist metoprolol by CFSE labeling. (**C**) The intracellular cAMP concentration of CF was determined by \[^125^I\] cAMP RIA KIT in different treatments. (**D**) Cell viability of CFs were pretreated with the PKA inhibitor H89 (1 μmol/ml) for 30 min before adding β~1~-AA (10 μg/ml). (**E**) Immunoblot detection of phosphorylated VASP (p-VASP) and total VASP form CFs stimulated with β~1~-AA (10 μg/ml) for 30 min. Images are representative of 3 independent repeated experiments. The bar graph shows the ratio of p-VASP to total VASP. (**F**) Immunoblot detection of phosphorylated VASP (p-VASP) and total VASP form CFs stimulated with β~1~-AA (10 μg/ml) for different time point in 60 min. n = 3 per group. ^\*\*^*P* \< 0.01 *vs.* vehicle (PBS) group, ^\#\#^*P* \< 0.01 *vs.* β~1~-AA group. VASP: vasodilator-stimulated phosphoprotein; P-VASP: phospho-vasodilator-stimulated phosphoprotein.](srep32430-f5){#f5}

![β~1~-AA might promote proliferation in cardiac fibroblast (CF) via β~2~-AR partially.\
(**A**) CFs were pretreated with the selective β~2~-AR antagonist ICI118551 (1 μmol/ml) for 30 min before treatment with β~1~-AA (10 μg/ml). Cell viability of CF were detected by CCK8 assay. ^\*\*^*P* \< 0.01 *vs.* IgG group, ^\#^*P* \< 0.05 *vs.* β~1~-AA group.^\#\#^*P* \< 0.01 *vs.* β~1~-AA group. (**B**) The intracellular cAMP concentration of CF was determined by \[^125^I\] cAMP RIA KIT in different treatments. ^\*\*^*P* \< 0.01 *vs.* IgG group, ^\#^*P* \< 0.05 *vs.* β~1~-AA group.^\#\#^*P* \< 0.01 *vs.* β~1~-AA group. (**C**) CFs were stimulated with β~1~-AA (0, 5, 10, 20 μg/ml) for 24 h, then β~2~-AR relative expression were unchaged by western blotting. ^\*^*P* \< 0.05 *vs.* vehicle group (0 μg/ml). (**D**) HA -β~1~-AR and flag-β~2~-AR were overexpressed on HEK293 cells by plasmid transfection. β~1~-AA interacted with HA-β~1~-AR but not flag-β~2~-AR by immunoprecipitation (a and b). The binding of β~1~-AA and β~1~-AR/β~2~-AR was detected by BLItz system (c and d). β~1~-AA bound to cell lysis of β~1~-AR overexpressed HEK293 cells, but not cell lysis of β~2~-AR overexpression-HEK293 cells (**C**). β~1~-AA bound to cell lysis of β~1~-AR overexpressed-HEK293 cells which were pre-bound to purchased anti-β~1~-AR, but not cell lysis of β~2~-AR overexpressed HEK293 cells which were pre-bound to purchased anti-β~2~-AR (**D**). Data shown here are representative of one of three individual experiments with similar results.](srep32430-f6){#f6}

![β~1~-AA promoted proliferition in cardiac fibroblast through.activating the P38MAPK and ERK1/2.\
(**A**) CFs were stimulated with β~1~-AA (0, 0.1, 1, 10 μg/ml) for 30 min, then phospharylated p38MAPK and total p38MAPK were detected by western blot. (**B**) Immunoblot detection of phosphorylated p38MAPK (p-p38MAPK) and total VASP form CFs stimulated with β~1~-AA (10 μg/ml) at 0, 5, 10, 15, 30 and 60 min. (**C**) Cell viability of CFs were pretreated with the P38MAPK inhibitor SB203580 (1 μmol/ml) for 30 min before adding β~1~-AA (10 μg/ml). (**D**) CFs were stimulated with β~1~-AA (0, 0.1, 1, 10 μg/ml) for 30 min, then phospharylated ERK1/2 and total ERK1/2 were detected by western blot. (**E**) Cell viability of CFs were pretreated with the ERK1/2 inhibitor PD98059 (1 μmol/ml) for 30 min before adding β~1~-AA (10 μg/ml). Data shown here are representative of one of three individual experiments with similar results. n = 3 per group. ^\*\*^*P* \< 0.01 *vs.* vehicle (PBS) group.](srep32430-f7){#f7}

![The conditioned medium of cardiac fibroblasts (CFs) treated with β~1~-AA increased early apoptosis in cardiomyocytes.\
(**A**) The conditioned medium of CFs stimulated with β~1~-AA for 24 h after neutralizing β~1~-AA using β~1~-AR-EC ~II~ were added to neonatal rat cardiomyocytes for 24 h, cell early apoptosis was evaluated by Annexin V/PI apoptosis kit. Data shown here are representative of one of three individual experiments with similar results. (**B**) The supernatant of CFs stimulated by β~1~-AA for 24 h promoted the early apoptosis of H9c2 cell lines in 24 h. ^\*\*^*P* \< 0.01 *vs.* conditional medium of CFs treated with IgG group. ^\#^*P* \< 0.01 *vs.* conditional medium of CFs treated with β~1~-AA group.](srep32430-f8){#f8}
